Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-07-21
2000-06-27
Caputa, Anthony C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, A61K 3818
Patent
active
060807202
ABSTRACT:
This invention relates to a composition for metabolic bone diseaese and/or bone fractures which comprises a pharmaceutically acceptable carrier and human neurotrophin-3 (NT-3).
This invention also relates to a method for the treatment and/or prevention of metabolic bone diseaese or bone fractures which comprises administering to a patient in need of said treatment and/or prevention a medicament containing an effective amount of human neurotrophin-3 (NT-3).
REFERENCES:
Skup, M.H. et al., NeuroReport, 5:1105-1109, May 1994.
Merck Manual, 16.sup.th Edition, Robert Berkow(ed.), Merck Research Laboratories, Rahway, N.J., 1992, pp. 1359-1360.
Kalcheim et al., "Neurotrophin 3 is a Mitogen for Cultured Neural Crest Cells," Proc. Natl. Acad. Sci. USA 89:1661-65 (1992).
Snider, W., "Functions of the Neurotrophins During Nervous System Development: What the Knockouts are Teaching Us," Cell 77:627-38 (1994).
Boulton et al., "ERKs: A Family of Protein-Serine/Threonine Kinases that are Activated and Tyrosine Phosphorylated in Response to Insulin and NGF," Cell 65:663-75 (1991).
Nakanishi et al., "Expression of Nerve Growth Factor Family Neurotrophins in a Mouse Osteoblastic Cell Line," Biochem. and Biophys. Res. Communications 198(3)891-97 (1994).
Kodama et al., "Establishment of a Clonal Osteogenic Cell Line from Newborn Mouse Calvaria," Jpn. J. Oral Biol. 23:899-901 (1981).
Grynkiewicz et al., "A New Generation of Ca.sup.2+ Indicators with Greatly Improved Fluorescence Properties," J. Biol. Chem. 260(6):3440-50 (1985).
Sambrook et al., Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press 1989), pp. 5.61; 5.64-5.72.
Sanger et al., "DNA Sequencing with Chain-Terminating Inhibitors," Proc. Natl. Acad. Sci. USA 74(12) 5463-67 (1977).
Merlio et al., "Molecular Cloning of Rat trkC and Distribution of Cells Expressing Messenger RNAs for members of the trk Family in the Rat Central Nervous System," Neurosci. 51(3):513-32 (1992).
Lamballe et al., "trkC, a New Member of the trk Family of Tyrosine Protein Kinases, Is a Receptor for Neurotrophin-3," Cell 66:967-79 (1991).
Ikeuchi et al., "Neurotrophic Factor Family and trk Gene Products," Experimental Medicine 10(3):126-31 (1992). (with English translation).
Oshimura et al., "Chromosome Ingression by the Micronucleus Fusion Method," Biotechnology 7(2):89-92 (1989). (with English translation).
Kudo Akira
Nakanishi Tohru
Takigawa Masaharu
Caputa Anthony C.
Gucker Stephen
Hoechst Japan Limited
LandOfFree
Treatment method of bone and osteoblasts with neurotrophin-3 (NT does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment method of bone and osteoblasts with neurotrophin-3 (NT, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment method of bone and osteoblasts with neurotrophin-3 (NT will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1784826